Yield10 Bioscience Announces Third Quarter 2019 Financial Results
"We are working to advance key initiatives and achieve several milestones further demonstrating the commercial path for our traits in the months ahead," said
"We have begun a transition into a development stage company, one actively engaging in commercialization efforts by identifying partners and processes we believe will scale our
"In the third quarter, we expanded our research agreement with Bayer for evaluation of our C3004 trait in soybean. In October, we signed a research agreement with Simplot, a major, privately held food and agribusiness company, to test three of our novel traits in potato. Both of these are examples of market leaders deploying and testing our innovative performance traits in crops of commercial significance.
“We are also well-positioned to capture value from our investments and capabilities in Camelina as a platform for producing specialty oils as well as other products of commercial interest, such as PHB biomaterials for water treatment. In 2019, we filed new patent applications including one covering the use of gene combinations to boost oil content in crops, and another on breakthrough technology for making PHB biomaterials in Camelina. We are pursuing new opportunities for collaboration based on Camelina as a production platform.
“We look forward to completing the analysis of data from our field tests of several traits in Camelina and canola, and reporting the data in the first quarter of 2020. We have progressed several traits this year, including C3003, C3004, and our CRISPR oil content traits such as C3008, C3009 and C3007. We expect to have many options for configuring our 2020 field tests with a desired goal of generating research and field data that support the creation of collaborations and other opportunities for revenue generation. Our traits represent potentially game-changing technology in agriculture that could allow the development of new crops with advanced performance and compositional profiles,” Dr. Peoples said.
Recent Progress Achieving 2019 Milestones
Expanded the research agreement with Bayer for evaluation of a new discovery related to the C3004 yield trait gene in soybean. Under the amended research license, Bayer will have access to new developments from Yield10’s C3004 program based on advanced technology related to the C3004 trait and its potential to increase seed yield.
Signed a research agreement with
Presented research showcasing the Camelina Platform for producing PHB biomaterials to improve water quality. At the 3rd
Presented research highlighting the Camelina Platform for producing specialty oils for use in food and animal feed. At the 7th
THIRD QUARTER 2019 FINANCIAL OVERVIEW
The Company ended the third quarter of 2019 with
The Company's present capital resources will not be sufficient to fund its planned operations for a twelve-month period and, therefore, raise substantial doubt about the Company's ability to continue as a going concern. The Company's ability to continue operations after its current cash resources are exhausted depends on its ability to obtain additional financing, including public or private equity financing, secured or unsecured debt financing, and receipt of additional government research grants, as well as licensing or other collaborative arrangements.
Operations
The Company’s net cash used by operating activities during the third quarter of 2019 was
For the third quarter ending
Total research grant revenue of
During the nine months ending
Total year to date grant revenue earned through
About
For more information visit www.yield10bio.com (
Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, expectations regarding Yield10’s cash position, cash forecasts and runway, ability to obtain sufficient financing to continue operating, expectations related to research and development activities, collaborations, intellectual property, the expected regulatory path for traits, reproducibility of data from field tests, the timing of completion of additional greenhouse and field test studies, the signing of research licenses and collaborations, and value creation as well as the overall progress of
Contacts:
Investor Relations:
Managing Director, CORE IR
Media Inquiries:
FischTank Marketing and PR
YIELD10 BIOSCIENCE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
UNAUDITED
(In thousands, except share and per share amounts)
| Three Months Ended September 30, |
Nine Months Ended September 30, |
||||||||||||||||||||||||||||||
| 2019 | 2018 | 2019 | 2018 | ||||||||||||||||||||||||||||
| Revenue: | |||||||||||||||||||||||||||||||
| Grant revenue | $ | 224 | $ | 76 | $ | 666 | $ | 421 | |||||||||||||||||||||||
| Total revenue | 224 | 76 | 666 | 421 | |||||||||||||||||||||||||||
| Expenses: | |||||||||||||||||||||||||||||||
| Research and development | 1,232 | 1,335 | 3,646 | 3,696 | |||||||||||||||||||||||||||
| General and administrative | 990 | 1,417 | 3,201 | 4,149 | |||||||||||||||||||||||||||
| Total expenses | 2,222 | 2,752 | 6,847 | 7,845 | |||||||||||||||||||||||||||
| Loss from operations | (1,998 | ) | (2,676 | ) | (6,181 | ) | (7,424 | ) | |||||||||||||||||||||||
| Other income (expense), net | 16 | 38 | 68 | 101 | |||||||||||||||||||||||||||
| Net loss | $ | (1,982 | ) | $ | (2,638 | ) | $ | (6,113 | ) | $ | (7,323 | ) | |||||||||||||||||||
| Basic and diluted net loss per share | $ | (0.16 | ) | $ | (0.26 | ) | $ | (0.52 | ) | $ | (0.74 | ) | |||||||||||||||||||
| Number of shares used in per share calculations: | |||||||||||||||||||||||||||||||
| Basic and diluted | 12,518,753 | 10,010,762 | 11,846,176 | 9,901,459 | |||||||||||||||||||||||||||
YIELD10 BIOSCIENCE, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
UNAUDITED
(In thousands, except share and per share amounts)
| September 30, 2019 |
December 31, 2018 |
||||||||||
| Assets | |||||||||||
| Current Assets: | |||||||||||
| Cash and cash equivalents | $ | 2,877 | $ | 3,023 | |||||||
| Short-term investments | — | 2,746 | |||||||||
| Accounts receivable | 71 | 94 | |||||||||
| Unbilled receivables | 83 | 66 | |||||||||
| Prepaid expenses and other current assets | 468 | 448 | |||||||||
| Total current assets | 3,499 | 6,377 | |||||||||
| Restricted cash | 332 | 332 | |||||||||
| Property and equipment, net | 1,247 | 1,385 | |||||||||
| Right-of-use assets | 4,310 | 4,766 | |||||||||
| Other assets | 31 | 100 | |||||||||
| Total assets | $ | 9,419 | $ | 12,960 | |||||||
| Liabilities and Stockholders’ Equity | |||||||||||
| Current Liabilities: | |||||||||||
| Accounts payable | $ | 51 | $ | 117 | |||||||
| Accrued expenses | 905 | 680 | |||||||||
| Lease liabilities | 798 | 844 | |||||||||
| Total current liabilities | 1,754 | 1,641 | |||||||||
| Lease liabilities, net of current portion | 5,045 | 5,621 | |||||||||
| Total liabilities | 6,799 | 7,262 | |||||||||
| Commitments and contingencies | |||||||||||
| Stockholders’ Equity: | |||||||||||
| Preferred stock ($0.01 par value per share); 5,000,000 shares authorized; no shares issued or outstanding | — | — | |||||||||
| Common stock ($0.01 par value per share); 60,000,000 shares authorized at September 30, 2019 and December 31, 2018; 12,519,017 and 10,025,811 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively | 125 | 100 | |||||||||
| Additional paid-in capital | 360,670 | 357,646 | |||||||||
| Accumulated other comprehensive loss | (124 | ) | (110 | ) | |||||||
| Accumulated deficit | (358,051 | ) | (351,938 | ) | |||||||
| Total stockholders’ equity | 2,620 | 5,698 | |||||||||
| Total liabilities and stockholders’ equity | $ | 9,419 | $ | 12,960 | |||||||
YIELD10 BIOSCIENCE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
UNAUDITED
(In thousands)
| Nine Months Ended September 30, |
|||||||||||||||
| 2019 | 2018 | ||||||||||||||
| Cash flows from operating activities | |||||||||||||||
| Net loss | $ | (6,113 | ) | $ | (7,323 | ) | |||||||||
| Adjustments to reconcile net loss to cash used in operating activities: | |||||||||||||||
| Depreciation | 150 | 146 | |||||||||||||
| Charge for 401(k) company common stock match | 73 | 91 | |||||||||||||
| Stock-based compensation | 406 | 952 | |||||||||||||
| Non-cash lease expense | 456 | 431 | |||||||||||||
| Changes in operating assets and liabilities: | |||||||||||||||
| Accounts receivables | 23 | 29 | |||||||||||||
| Unbilled receivables | (17 | ) | 36 | ||||||||||||
| Prepaid expenses and other assets | 217 | (70 | ) | ||||||||||||
| Accounts payable | (66 | ) | (37 | ) | |||||||||||
| Accrued expenses | 48 | (756 | ) | ||||||||||||
| Lease liabilities | (622 | ) | (230 | ) | |||||||||||
| Net cash used for operating activities | (5,445 | ) | (6,731 | ) | |||||||||||
| Cash flows from investing activities | |||||||||||||||
| Purchase of property and equipment | (12 | ) | (42 | ) | |||||||||||
| Purchase of short-term investments | (1,000 | ) | (9,742 | ) | |||||||||||
| Proceeds from the sale and maturity of short-term investments | 3,746 | 5,250 | |||||||||||||
| Net cash provided by (used for) investing activities | 2,734 | (4,534 | ) | ||||||||||||
| Cash flows from financing activities | |||||||||||||||
| Proceeds from warrants exercised | — | 124 | |||||||||||||
| Taxes paid on employees' behalf related to vesting of stock awards | (4 | ) | (6 | ) | |||||||||||
| Proceeds from registered direct offering, net of issuance costs | 2,583 | — | |||||||||||||
| Net cash provided by financing activities | 2,579 | 118 | |||||||||||||
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | (14 | ) | (19 | ) | |||||||||||
| Net decrease in cash, cash equivalents and restricted cash | (146 | ) | (11,166 | ) | |||||||||||
| Cash, cash equivalents and restricted cash at beginning of period | 3,355 | 14,804 | |||||||||||||
| Cash, cash equivalents and restricted cash at end of period | $ | 3,209 | $ | 3,638 | |||||||||||
| Supplemental disclosure of non-cash information: | |||||||||||||||
| Purchase of property and equipment included in accounts payable and accrued expenses | $ | 41 | $ | — | |||||||||||
| Right-of-use assets acquired in exchange for lease liabilities | $ | — | $ | 194 | |||||||||||
Source: Yield10 Bioscience, Inc.
